SB 140 creates a new chapter in the Indiana Code regulating pharmacy benefits in health plans, effective for policies and contracts issued, renewed, entered into, or amended after December 31, 2025. The bill defines key terms such as pharmacy benefit manager (PBM), health plan, insurer, pharmacy affiliate, actual acquisition cost, net amount, and cost sharing, and it generally applies to commercial health coverage while excluding Medicaid, most managed care organizations, Medicare Part D, and most state employee health plans except as specifically provided.
The core of the bill is a set of network, contracting, reimbursement, and anti-steering rules for insurers, PBMs, and other pharmacy-benefit administrators. It requires pharmacy networks to be reasonably adequate and accessible, including a minimum standard of non-mail-order pharmacy access within 30 miles of an insured’s residence, and it requires annual reporting to the insurance commissioner. The bill also restricts retroactive claim denials and recoupments except in cases of fraud or actual overpayment, prohibits reimbursement below specified benchmarks, bars certain dispensing-fee recoupments when the correct medication was dispensed, and limits practices that favor affiliated pharmacies over independent pharmacies.
SB 140 further protects pharmacies and pharmacists from being forced into affiliate arrangements or discriminatory contract terms, and it preserves their ability to tell patients about lower-cost alternatives. It also gives insureds, pharmacies, and pharmacists a complaint process with the commissioner, authorizes investigation and written determinations, and allows reimbursement orders for monetary losses caused by violations. For state employee health plans, the bill requires the state personnel department to either create an internal PBM or contract with an outside administrator, and it declares that data collected by a contractor under that arrangement belongs to the state.
The bill’s impact on Indiana law is significant because it adds a detailed regulatory framework for PBM conduct and pharmacy reimbursement, expanding the insurance commissioner’s oversight role and creating enforceable standards for network adequacy, pricing, and affiliate conduct. It also affects third-party administrators by prohibiting them from conditioning contracts on the selection of a particular PBM or charging different fees based on PBM choice for self-funded plans with more than 100 employees or members. The act includes a legislative study directive on pharmacy benefit coverage contracts for Medicaid and state employee health plans, and it contains an emergency clause.
The overall sentiment reflected in the vote history appears strongly favorable and bipartisan, with large majorities in both chambers and only a small number of dissenting votes. The main points of contention are not documented in committee transcripts, but the structure of the bill suggests likely concerns around PBM regulation, limits on affiliated pharmacy steering, reimbursement floor requirements, and the administrative burden of reporting and compliance. The narrower vote margins on the conference committee report, especially in the Senate, suggest some lingering disagreement over the final compromise even though the bill ultimately advanced with broad support.
The bill adds IC 27-1-24.2, establishing statewide rules for pharmacy benefit managers, insurers, and other pharmacy-benefit administrators in commercial health plans. It imposes network adequacy standards, anti-steering and anti-discrimination rules, reimbursement floors tied to acquisition cost or NADAC plus dispensing fees, limits on retroactive recoupments, complaint and enforcement procedures through the insurance commissioner, and special provisions for state employee health plans and certain self-funded plan sponsors. It also directs a legislative study on Medicaid and state employee pharmacy benefit contracting.
The vote history indicates broad support for the bill, with overwhelming passage in the Senate and House and only a few dissenting votes. The conference committee report also passed comfortably, though with somewhat more opposition in the Senate than earlier stages. No committee transcript is available, but the final action suggests the bill was viewed as a significant but generally acceptable reform of pharmacy benefit practices.
Likely areas of contention include the bill’s restrictions on PBM and insurer contracting practices, especially limits on affiliated-pharmacy steering, reimbursement minimums, and bans on retroactive claim denials and recoupments. Independent pharmacies and consumer advocates would likely favor these protections, while insurers, PBMs, and plan administrators may object to increased regulation, compliance costs, and reduced flexibility in network design and pricing. The special treatment of state employee health plans and the requirement that third-party administrators not tie contracts to a particular PBM may also have been debated.